SCHEMBL336731

SCHEMBL336731

C1C[C@@H]2CNCCN2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10758546 1.00
SCHEMBL271886 1.00
SCHEMBL63706 1.00
Hydrochloric Acid SCHEMBL3635377 0.98 HTR6 (0.83)
Hydrochloric Acid SCHEMBL3639440 0.98 HTR6 (0.83)
Bromide SCHEMBL23116331 0.98 HTR6 (0.83)
Hydrochloric Acid SCHEMBL3633006 0.98 HTR6 (0.83)
Bromide SCHEMBL23116334 0.98 HTR6 (0.83)
Hydrochloric Acid SCHEMBL3635374 0.98 HTR6 (0.83)
SCHEMBL1190916 0.93 HTR6 (1.00)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 373 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12384789-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2025-08-12 US claimed
CN-119528903-A Compounds for the treatment of spinal muscular atrophy PTC医疗公司 2025-02-28 CN claimed
CN-111065626-B Compounds for the treatment of huntington's disease PTC医疗公司 2024-09-27 CN claimed
WO-2024138018-A1 TREATMENT OF GEMIN5-MEDIATED DISORDERS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2024-06-27 WO claimed
US-20230331725-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2023-10-19 US claimed
EP-4151627-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC Therapeutics, Inc. (US) 2023-03-22 EP claimed
US-20220251098-A1 COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS, INC. 2022-08-11 US claimed
CN-104244944-B For treating the compound of spinal muscular atrophy PTC医疗公司 2018-06-08 CN claimed
CN-106674254-A Quinolone carboxylic acid compounds and intermediates, preparation method and application thereof 广东省中医院 2017-05-17 CN claimed
WO-2026085629-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2026-04-30 WO disclosed
EP-4731623-A1 CARBOLINE COMPOUNDS AND USE THEREOF PTC Therapeutics, Inc. (US) 2026-04-29 EP disclosed
US-12577226-B2 Compounds for treating Huntington's disease PTC THERAPEUTICS, INC. (US) 2026-03-17 US disclosed
US-20260028347-A1 HETEROCYCLIC AND HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE PTC THERAPEUTICS INC (US) 2026-01-29 US disclosed
US-20260008790-A1 COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY HOFFMANN-LA ROCHE INC. (US) 2026-01-08 US disclosed
WO-2006023400-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-03-02 WO disclosed
CN-1335850-A Quinoline derivatives SMITHKLINE BEECHMA PLC (GB) 2002-02-13 CN disclosed
EP-0797577-B1 BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY ALLELIX BIOPHARMA (CA) 2000-07-26 EP disclosed
EP-0797577-A1 BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY Allelix Biopharmaceuticals Inc. (CA) 1997-10-01 EP disclosed
US-5576314-A Bicyclic nonane and decane compounds having dopamine receptor affinity ALLELIX BIOPHARMACEUTICALS INC. (CA) 1996-11-19 US disclosed
WO-1996018630-A1 BICYCLIC NONANE AND DECANE COMPOUNDS HAVING DOPAMINE RECEPTOR AFFINITY ALLELIX BIOPHARMACEUTICALS INC. (CA) 1996-06-20 WO disclosed